Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

Cancer research - 1 Aug 2017

Tateishi Kensuke, Higuchi Fumi, Miller Julie J, Koerner Mara V A, Lelic Nina, Shankar Ganesh M, Tanaka Shota, Fisher David E, Batchelor Tracy T, Iafrate A John, Wakimoto Hiroaki, Chi Andrew S, Cahill Daniel P

Abstract excerpt

IDH1-mutant gliomas are dependent upon the canonical coenzyme NAD+ for survival. It is known that PARP activation consumes NAD+ during base excision repair (BER) of chemotherapy-induced DNA damage. We therefore hypothesized that a strategy combining NAD+ biosynthesis inhibitors with the alkylating chemotherapeutic agent temozolomide could potentiate NAD+ depletion-mediated cytotoxicity in mutant IDH1 cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Nicotinamide Phosphoribosyltransferase

Share to Piperidines

Share to Random Allocation

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 28625978
DOI: 10.1158/0008-5472.CAN-16-2263
PMCID: PMC5783559

Genes

IDH1
NAMPT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.PMID 28625978Read ↗

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Semantic proximity Read ↗

Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities.Semantic proximity Read ↗

NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in CancerSemantic proximity Read ↗

Targeting NAD+ metabolism: dual roles in cancer treatmentSemantic proximity Read ↗

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.Semantic proximity Read ↗

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.Semantic proximity Read ↗

NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.Semantic proximity Read ↗

Advances in NAD-Lowering Agents for Cancer TreatmentSemantic proximity Read ↗

Cancer cells are sensitive to wild-type IDH1 inhibition under nutrient limitationSemantic proximity Read ↗

A prognostic NAD+ metabolism-related gene signature for predicting response to immune checkpoint inhibitor in gliomaSemantic proximity Read ↗

NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.Semantic proximity Read ↗

An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.